|
Match
|
Document |
Document Title |
|
|
7399827 |
Page-4, an x-linked gage-like gene expressed in normal and neoplastic prostate, testis and uterus, and uses therefor
PAGE-4 is a gene preferentially expressed in normal male and female reproductive tissues, prostate, testis, fallopian tube, uterus and placenta, as well as in prostate cancer, testicular cancer and...
|
|
|
7364741 |
Peptides of human Papilloma virus for use in human T cell response inducing compositions
A peptide comprising an amino acid sequence derived from a human papilloma virus (HPV) protein, wherein said amino acid sequence has the ability to bind to a human Major Histocompatibility Complex...
|
|
|
7345026 |
Hybrid or chimeric polynucleotides, proteins, and compositions comprising hepatitis B virus sequences
H-2 class I negative, HLA-A2.1 transgeniic HHD mice were used for a comparative evaluation of the immunogenicity of HLA-A2.1 restricted human tumor-associated CTL epitopes. A hierarchy was...
|
|
|
7264965 |
Method for producing or enhancing a T-cell response against a target cell using a complex comprising an HLA class I molecule and an attaching means
A complex including an HLA class I molecule and attaching means for selectively attaching the HLA class I molecule to a target is disclosed, and a method is provided for producing or enhancing an...
|
|
|
7252829 |
HLA binding peptides and their uses
The present invention provides the means and methods for selecting immunogenic peptides and the immunogenic peptide compositions capable of specifically binding glycoproteins encoded by HLA alleles...
|
|
|
7195758 |
Methods of inducing a T cell mediated immune response by administering antigen presenting B cells
We teach a strategy to obtain large quantities of desired APCs, activated B cells, which are superior in their capacity to present tumor protein antigen in a multiadministration protocol. Human B...
|
|
|
7105157 |
Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
The present invention relates to cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells...
|
|
|
7101705 |
Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
Disclosed are cells and methods for treating or preventing tumor formation or infections with pathogens in a patient. The cells of the invention are antigen-presenting cells (e.g., dendritic cells...
|
|
|
7026443 |
Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions
This invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and prepare human papillomavirus (HPV) epitopes, and to develop epitope-based vaccines...
|
|
|
6911207 |
Cytotoxic T-cell epitopes of the papillomavirus L1-protein and use thereof in diagnostics and therapy
The present invention relates to a papillomavirus T-cell epitope having an amino acid sequence AQIFNKPYW, AGVDNRECI and/or to a functionally active variant thereof, also to their use in diagnostics...
|
|
|
6897288 |
Mage-A12 antigenic peptides and uses thereof
The invention provides antigenic peptides derived from MAGE-A12 polypeptides and presented by HLA molecules. Methods for diagnosis and treatment which involve the polypeptides also are provided.
|
|
|
6838084 |
Cytotoxic T-cell epitopes of the papilloma virus l1-protein and use thereof in diagnosis and therapy
The present invention relates to a papillomavirus T-cell epitope having an amino acid sequence ILVPKVSGL (SEQ ID NO: 1), RLVWACVGV (SEQ ID NO: 2), HLFNRAGTV (SEQ ID NO: 3), YLRREQMFV (SEQ ID NO:...
|
|
|
6716422 |
Vaccine adjuvants for immunotherapy of melanoma
The invention provides methods of inducing the production of cytolytic T lymphocytes directed against malignancy or infectious agent by a mammal and treating such disease such that deleterious side...
|
|
|
6670186 |
RNA-loaded antigen presenting cells
The present invention relates, in general, to RNA-loaded antigen presenting cells and, in particular, to methods for treating or preventing tumor formation or pathogen infection in a patient. The...
|
|
|
6623740 |
Structurally modified peptides that are resistant to peptidase degradation
Human melanoma cells bear antigens that are recognized by autologous CD8 + cytotoxic T-lymphocytes. The invention involves the reception of particular peptides analogues of the MZ2-E antigen by...
|
|
|
6555373 |
Methods for identifying human cell lines useful for endogenous gene activation isolated human cell lines identified thereby, and uses thereof
The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of...
|
|
|
6540994 |
Macrophages, process for preparing the same and their use as active substances of pharmaceutical compositions
The invention relates to macrophages which have at least one of the following properties: their cytotoxic activity without IFN-7 is increased by about 20 to 30% with respect to standard...
|
|
|
6482407 |
Membrane-bound cytokine compositions comprising GM-CSF or an active fragment thereof and methods of modulating and an immune response using the same
The present invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule operatively fused to a heterologous membrane...
|
|
|
6455046 |
Use of mCRP to enhance immune responses
The invention provides a method of enhancing an immune response to an immunogen in an animal. The method comprises administering to the animal an effective amount of the immunogen and an effective...
|
|
|
EP1235841A1 |
INDUCING CELLULAR IMMUNE RESPONSES TO MAGE2/3 USING PEPTIDE AND NUCLEIC ACID COMPOSITIONS
Abstract not available for EP1235841 Abstract of corresponding document: WO0142267 The invention uses our knowledge of the mechanisms by which antigen is recognized by T cells to identify and...
|
|
|
6419931 |
Compositions and methods for eliciting CTL immunity
Cytotoxic T lymphocyte responses are effectively induced to an antigen of interest, particularly viral, bacterial, parasitic and tumor antigens. Compositions, including pharmaceutical compositions,...
|
|
|
6280743 |
Use of mCRP to enhance immune responses
The invention provides a method of enhancing an immune response to an immunogen in an animal. The method comprises administering to the animal an effective amount of the immunogen and an effective...
|
|
|
6190670 |
Use of mCRP to enhance immune responses
The invention provides a method of enhancing an immune response to an immunogen in an animal. The method comprises administering to the animal an effective amount of the immunogen and an effective...
|
|
|
6080399 |
Vaccine adjuvants for immunotherapy of melanoma
The invention provides methods of inducing the production of cytolytic T lymphocytes directed against malignancy or infectious agent by a mammal and treating such disease such that deleterious side...
|
|
|
5891432 |
Membrane-bound cytokine compositions comprising GM=CSF and methods of modulating an immune response using same
The present invention provides a cellular vaccine having a membrane-bound fusion protein that includes a non-antibody immunomodulatory molecule such as GM-CSF operatively fused to a heterologous...
|